Sabril (Vigabatrin)

Vigabatrin is a medicine used to treat seizures in some people. It works by changing how the brain uses a chemical called GABA. This helps reduce the number of seizures a person has.

Brand names:Sabril
Medication

What people taking Sabril (Vigabatrin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Sabril (Vigabatrin) for Infantile Spasms?

NameHow it went

About Sabril (Vigabatrin)

What It's For

Vigabatrin is a prescription antiseizure medicine. In the US it is sold as Sabril (tablets, and a powder that is mixed into a liquid, both also available as generics) and as Vigafyde, a ready-to-use liquid. It has two approved uses, involving very different patients, and in both it is chosen only when the expected seizure benefit outweighs its risk of permanent vision loss. The first is infantile spasms, a serious seizure disorder that begins in babyhood. Vigabatrin is approved as a stand-alone treatment for infants 1 month to 2 years old, and Vigafyde is approved only for this use. Many guidelines favor hormone treatment (ACTH or the steroid prednisolone) as a first choice, sometimes combined with vigabatrin. Vigabatrin is the preferred first treatment when the spasms are caused by tuberous sclerosis complex (TSC), a rare genetic disease that causes benign growths in the brain and other organs, and for babies who cannot take hormone treatment. The second is complex partial seizures, a type of focal seizure (one that starts in one area of the brain), in adults and children 2 and older whose seizures have not been controlled by several other medicines. Here vigabatrin is added to the person's existing treatment. It is not used as a first medicine for this kind of epilepsy.

How It Works

GABA (gamma-aminobutyric acid) is a chemical messenger that calms nerve-cell activity in the brain. After it does its job, an enzyme called GABA transaminase breaks it down. Vigabatrin permanently disables that enzyme, so GABA builds up in the brain and nervous system. More GABA is thought to make nerve cells less likely to fire in the abnormal bursts that produce seizures, although exactly how this controls seizures is not fully understood. Because the enzyme is disabled rather than briefly blocked, the effect lasts until the body makes new enzyme, not just as long as the drug stays in the blood. This is one reason blood levels of vigabatrin are not used to guide the dose.

Dosage & Administration

Vigabatrin is taken by mouth twice a day, with or without food. Sabril tablets are 500 mg. Sabril powder comes in 500 mg packets that are mixed with water before each dose. Vigafyde is a liquid that needs no mixing and can also be given through a gastrostomy (G) feeding tube. Vigafyde is twice as concentrated as the mixed powder, so the same number of milliliters does not deliver the same dose. Check the product and strength whenever a prescription or pharmacy changes, and measure liquid doses with the oral syringe or measuring device provided, never a kitchen spoon. Treatment starts at a lower dose and is raised in steps: every week or so for older children and adults, and every few days for infants, whose doses are based on body weight. For adults with focal seizures, a higher dose than the usual recommended amount has not worked better and causes more side effects. People with reduced kidney function need a lower dose. Because of the vision risk, vigabatrin is available only through a restricted safety program called the Vigabatrin REMS (Risk Evaluation and Mitigation Strategy). The prescriber and the dispensing pharmacy must be certified, and the patient (or a parent for a child) must be enrolled. Do not stop vigabatrin suddenly. Stopping is done by lowering the dose gradually to avoid triggering withdrawal seizures.

Side Effects

The most important risk is permanent loss of vision. In adult studies, 30 percent or more of people developed narrowing of the visual field in both eyes, ranging from mild to severe. In severe cases only a small central area of sight remains (tunnel vision), which can be disabling. Vigabatrin can also damage the center of the retina and reduce sharpness of vision. The damage can begin within weeks or appear after months or years, the risk rises with higher doses and longer use, and no dose is known to be free of risk. Lost vision does not come back, and it can worsen even after the medicine is stopped. This loss of side vision is usually not noticed by the person or their caregivers until it is severe, and it is especially hard to detect in babies. That is why scheduled eye testing, described below, matters more than waiting for symptoms. Any change in vision that someone does notice should be reported to the prescriber promptly. In adults with focal seizures, the most common side effects are sleepiness, fatigue, dizziness, blurred or double vision, tremor and problems with coordination. Weight gain is common in both adults and children, and some adults develop swelling in the legs or numbness and tingling in the feet. Infants commonly become sleepy and in studies had more bronchitis and ear infections than infants on placebo. Some infants treated for infantile spasms show changes on brain MRI (magnetic resonance imaging) scans (in one study, 22 percent of vigabatrin-treated infants compared with 4 percent on other treatments). These changes generally went away after the medicine was stopped, but their long-term significance has not been well studied.

Interactions & Warnings

Vigabatrin is generally not used with other medicines that can harm the retina or cause glaucoma, or in people who already have, or are at high risk of, another type of permanent vision loss, unless the benefits clearly outweigh the risks. Bring a full list of medicines, including eye drops, to the prescriber and the eye specialist. It can lower the blood level of phenytoin (Dilantin), another antiseizure medicine, so that dose may need adjusting. It can raise levels of clonazepam (Klonopin), a sedating benzodiazepine also used for seizures, which can increase its side effects. It is unlikely to make birth control pills less effective. Because vigabatrin causes sleepiness and fatigue, people should not drive or operate machinery until they know how it affects them. Like all antiseizure medicines, vigabatrin carries a US Food and Drug Administration (FDA) warning about a small increase in suicidal thoughts and behavior. New or worsening depression, thoughts of self-harm, or unusual changes in mood or behavior should be reported to the prescriber right away. There are not enough human data to know vigabatrin's risk in pregnancy, but animal studies showed harm to the developing fetus. Anyone who is pregnant or planning pregnancy should discuss the balance of seizure control and medicine risk with the care team rather than stopping on their own, and can join the North American Antiepileptic Drug Pregnancy Registry. Vigabatrin passes into breast milk, and breastfeeding is not recommended while taking it.

What to Expect

Eye testing is part of treatment from the start. A vision assessment is recommended no later than 4 weeks after starting, at least every 3 months while taking vigabatrin, and again about 3 to 6 months after stopping. It is done by an eye specialist experienced in visual field testing, which maps how far a person can see to the sides. Babies and others who cannot do that test may have other exams, such as a test of the retina's electrical response (electroretinography) or a detailed scan of the retina. Testing cannot always prevent damage, because loss can progress between visits. Its purpose is to catch changes early enough to weigh stopping the medicine. The benefit of vigabatrin, when it works, is usually visible fairly soon, and the decision to continue depends on it. For infantile spasms, the response is typically checked clinically and with an EEG (a recording of brain waves) after about two weeks, and vigabatrin should be stopped if there is no substantial benefit within 2 to 4 weeks. For focal seizures, it should be stopped if there is no substantial benefit within 3 months. The aim is the lowest dose for the shortest time that achieves the goal. For people who do benefit, the need for vigabatrin is reassessed regularly, weighing seizure control against the growing total exposure. Stopping is always done gradually under the care team's direction.

Questions to Ask Your Doctor

  1. 1.Why is vigabatrin the right choice for this situation compared with hormone treatment or other seizure medicines?
  2. 2.How will we judge whether it is working, and when would we decide to stop it?
  3. 3.Who will do the vision testing, how often, and what would we do if the tests show a change?
  4. 4.Which form should we use, and how do I measure each dose accurately?
  5. 5.How do the other medicines, eye conditions or pregnancy plans in our family's situation affect this decision?

Last reviewed • Oct 2026

Educational content, not medical advice.